10 February 2011
Sareum Holdings plc
("Sareum" or "the Company")
Placing to raise £500,000
The Company announces that, following investor demand, it has conditionally
raised £500,000, before expenses, by way of a placing by Hybridan LLP of
50,000,000 new ordinary shares of 0.025p each in the capital of the Company (the
"Placing Shares") at 1p per share, representing a 40 per cent. discount to the
closing market price of 1.65 pence on 8 February 2011, the price which formed
the basis for the Board's decision to undertake the placing. The Placing Shares
have been issued to Xcap Securities plc, on behalf of its clients.
Following the results of the recent study that was announced on 7 February 2011
Sareum intends to use the proceeds of the placing to accelerate the advancement
of the Aurora+FLT3 Kinase leukaemia drug discovery programme and for working
capital generally.
It is the Board's view that the placing is the most appropriate means of
providing capital to accelerate its drug discovery programmes and to provide
working capital for the Company. The cost of funds raised through the placing
are substantially less than those for an open offer or a rights issue to
shareholders.
Application will be made to the London Stock Exchange for the Placing Shares to
be admitted to trading on AIM and it is expected that admission will become
effective and trading will commence on 15 February 2011. The Placing Shares will
rank pari passu with the existing ordinary shares of the Company.
Following the admission of the Placing Shares to trading on AIM, the Company
will have a total of 1,450,597,713 shares in issue.
Enquiries:
Sareum Holdings plc
Tim Mitchell 01223 497 700
Merchant Securities Limited (NOMAD)
Simon Clements/Bidhi Bhoma 020 7628 2200
Hybridan LLP (Broker)
Claire Noyce 020 7947 4350
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: SAREUM HOLDINGS PLC via Thomson Reuters ONE
[HUG#1487359]
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.